Andrew R. Boll
2022
In 2022, Andrew R. Boll earned a total compensation of $764.4K as Chief Financial Officer and Corporate Secretary at Imprimis Pharmaceuticals, a 77% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $285,225 |
|---|---|
| Salary | $416,427 |
| Other | $62,734 |
| Total | $764,386 |
Boll received $416.4K in salary, accounting for 54% of the total pay in 2022.
Boll also received $285.2K in non-equity incentive plan and $62.7K in other compensation.
Rankings
In 2022, Andrew R. Boll's compensation ranked 3,591st out of 5,717 executives tracked by ExecPay. In other words, Boll earned more than 37.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,591 out of 5,717 | 37th |
Division Manufacturing | 2,039 out of 3,111 | 35th |
Major group Chemicals And Allied Products | 975 out of 1,410 | 31st |
Industry group Drugs | 912 out of 1,311 | 30th |
Industry Pharmaceutical Preparations | 663 out of 957 | 31st |
Source: SEC filing on April 28, 2023.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2022.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019